Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

OPTIMIZATION OF SALMONELLE-HIV-1 DNA VACCINE VECTORS

Award Number: R01AI055367
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2003
PERIOD OF PERFORMANCE END DATE: 01/31/2010

Group Awards By:

View Award Description

OPTIMIZATION OF SALMONELLE-HIV-1 DNA VACCINE VECTORS - DESCRIPTION (provided by applicant): The goal of the research in this proposal is to identify a Salmonella HIV-1 DNA vaccine vector configuration that induces durable, high-titer neutralizing antibody responses to HIV-1 in the mucosal and systemic immune compartments. The capacity of Salmonella vectors to deliver DNA vaccines and induce immune responses in the mucosal and systemic compartments supports the idea to deploy this vector to deliver DNA vaccines that express conformationally constrained HIV-1 Env immunogens. Moreover, strong humoral responses to gp120 developed in mice primed with a Salmonella gp120 DNA vaccine vector following two parenteral booster vaccinations with gp120 protein; in contrast, no such responses occurred in mice primed with the control Salmonella construct and boosted twice with gp120 protein (Section 3.3). The significance of having identified an effective vaccination protocol for the induction of high-titer antibody responses to a model HIV-1 antigen following a mucosal prime will not be overlooked. However, the Principal Investigator (PI) proposes that the complete utilization of this inexpensive oral vaccine vector necessitates that such responses arise without a heterologous vaccine modality boosts. In this regard, the responses induced by a first-generation Salmonella Env/gp120 DNA vaccine vectors to HIV-1 were predominantly cell-mediated ((1); App. 1). Nonetheless, the afore mentioned humoral priming attribute suggests the occurrence of low-dose immunogen expression, which induced memory T helper and B cell responses (12-16). By extension, the central hypothesis of this proposal is that the magnitude of the antibody responses to HIV-1 following vaccination with a Salmonella HIV-1 DNA vaccine vector is directly linked to the efficiency DNA vaccine delivery and immunogen expression in host cells. To test this hypothesis the potency and duration of mucosal and systemic antibody responses will be measured in mice vaccinated with Salmonella vectors that carry modifications designed to optimize DNA vaccine delivery and immunogen expression. It is projected that this approach will provide fundamental information germane to the development of an inexpensive oral HIV-1 vaccine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2009 ( Subtotal = $250,370 )
2009	2009	BACILLIGEN INC	9700 GREAT SENECA HIGHWAY	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	7	2/16/2009	SUPPLEMENT FOR EXPANSION	$250,370
														Subtotal = $250,370

Issue Date FY: 2007 ( Subtotal = $438,628 )
2007	2007	BACILLIGEN INC	9700 GREAT SENECA HIGHWAY	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	7	3/6/2007	NON-COMPETING CONTINUATION	$438,628
														Subtotal = $438,628

Issue Date FY: 2006 ( Subtotal = $378,394 )
2006	2006	BACILLIGEN INC	9700 GREAT SENECA HIGHWAY	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	6	9/29/2006	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$230,511
2006	2006	AERAS GLOBAL TB FOUNDATION	7500 old georgetown rd, #800	BETHESDA	MD	20814	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	5	2/15/2006	NON-COMPETING CONTINUATION	$147,883
														Subtotal = $378,394

Issue Date FY: 2005 ( Subtotal = $387,500 )
2005	2005	AERAS GLOBAL TB FOUNDATION							Microbiology and Infectious Diseases Research	000	4	8/10/2005	NON-COMPETING CONTINUATION	$387,500
														Subtotal = $387,500

Issue Date FY: 2004 ( Subtotal = $372,500 )
2004	2004	AERAS GLOBAL TB FOUNDATION	9610 MEDICAL CENTER DR STE 220	ROCKVILLE	MD	20850	MONTGOMERY	USA	Microbiology and Infectious Diseases Research	000	3	3/5/2004	NON-COMPETING CONTINUATION	$372,500
														Subtotal = $372,500

Issue Date FY: 2003 ( Subtotal = $366,906 )
2003	2003	MARYLAND BIOTECHNOLOGY INSTITUTE	701 E PRATT STREET, SUITE 200	BALTIMORE	MD	21202	BALTIMORE CITY	USA	Microbiology and Infectious Diseases Research	000	1		NEW	$113,256
2003	2003	AERAS GLOBAL TB FOUNDATION	9610 MEDICAL CENTER DR STE 220	ROCKVILLE	MD	20850	MONTGOMERY	USA	Microbiology and Infectious Diseases Research	000	2	9/8/2003	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$253,650
														Subtotal = $366,906

Grand Total All Awards = $2,194,298

Top

All Categories

About

Search

Reports

Data Submission

Award Information

OPTIMIZATION OF SALMONELLE-HIV-1 DNA VACCINE VECTORS

Award Number: R01AI055367

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2003

PERIOD OF PERFORMANCE END DATE: 01/31/2010

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer